Evenity denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for evenity are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Evenity as Duplicate Therapy

Evenity (romosozumab) is a bone-forming agent approved for osteoporosis in postmenopausal women at high fracture risk. Aetna issues "duplicate therapy" denials when the member is currently taking — or has recently taken — another bone-density-building agent, most often an anabolic therapy such as teriparatide or abaloparatide. Because these agents work through overlapping or potentially antagonistic mechanisms, Aetna's clinical policy typically precludes concurrent use. The denial does not mean Evenity is never appropriate; it means the plan needs documentation that the current treatment sequence is clinically justified.

## Why This Denial Is Appealable

A duplicate-therapy denial is appealable when the clinical record shows that the concurrent or sequential use is clinically intentional and evidence-based, that the prior therapy has been or is being discontinued, or that the treating physician has determined that the combination or sequence is appropriate for this patient's specific fracture-risk profile. You are entitled to a full internal appeal under ERISA §503 or your state insurance law, and to independent external review under ACA §2719 after exhausting internal remedies, generally within approximately four months of the final internal denial.

## Your Appeal Timeline

1. Request the denial letter and Aetna's operative clinical policy for Evenity. 2. Identify exactly which concurrent agent triggered the duplicate-therapy flag. 3. File a first-level internal appeal within the deadline on your Explanation of Benefits. 4. Request external review if the internal appeal is denied.

## Documentation to Gather

• Diagnosis confirmation: DXA scan reports and fracture risk assessment establishing severe osteoporosis or high fracture risk.
• Current and prior medication list with dates: Pharmacy records showing what was started, stopped, and when — demonstrating that the therapies are sequential rather than concurrent, or explaining the clinical rationale if concurrent.
• Prescriber medical-necessity letter: A letter from your endocrinologist or treating physician explaining the intended treatment sequence, why Evenity is appropriate at this point, and addressing the specific agent Aetna identified as creating duplication.
• Applicable guideline reference: The physician's letter may reference the applicable Endocrine Society or American Society for Bone and Mineral Research (ASBMR) guideline organization for osteoporosis management sequencing.

## Criteria-Mapping Structure

Obtain Aetna's clinical policy for Evenity and identify the duplicate-therapy exclusion language. Then:

| Policy Requirement | Your Chart Evidence | |---|---| | No concurrent anabolic agent in use | Cite stop date of prior agent from pharmacy records | | Sequential use is clinically justified | Cite prescriber letter explaining treatment plan | | Diagnosis meets coverage criteria | Cite DXA report and fracture history |

Demonstrating clear discontinuation dates and a documented clinical rationale for the treatment sequence is the key to overturning an Evenity duplicate-therapy denial.